Tiziana Life Sciences announced that it had received non-dilutive funding of $3.4M. Gabriele Cerrone, Chairman, acting CEO and founder of Tiziana Life Sciences commented, “Tiziana is pleased to receive $3.4M in non-dilutive funding to support our ongoing Phase 2 trial of intranasal foralumab in non-active secondary progressive multiple sclerosis as well as our work in Alzheimer’s Disease. We continue to explore all avenues to pursue further non-dilutive funding in the near term.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLSA:
- Tiziana Receives $3.4 Million in Non-Dilutive Funding
- Tiziana Advances Alzheimer’s Treatment with FDA Nod
- Tiziana Life to dose first patient with moderate Alzheimer’s with foralumab
- Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer’s Disease with Foralumab
- Tiziana’s MS Drug Fast Track Submission Accepted